Xyrem purchasers win class certification

A California federal judge has granted class status to indirect purchasers in the Xyrem antitrust litigation, rejecting several drugmakers’ claims that many class members would remain “brand loyal” even if generic narcolepsy treatments entered the market earlier.

Unlock unlimited access to all Global Competition Review content